Xbrane Biopharma AB publ announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was SEK 2.486 million. Operating loss was SEK 58.413 million compared to SEK 53.197 million a year ago. Net loss was SEK 59.168 million compared to SEK 53.397 million a year ago. Basic loss per share from continuing operations was SEK 2.67 compared to SEK 3.11 a year ago. For the half year, sales was SEK 2.486 million. Operating loss was SEK 109.823 million compared to SEK 104.825 million a year ago. Net loss was SEK 110.435 million compared to SEK 105.231 million a year ago. Basic loss per share from continuing operations was SEK 4.97 compared to SEK 6.12 a year ago.